[1]文琰 杨谋 胡宏德.梗阻性肥厚型心肌病缓解梗阻的治疗进展[J].心血管病学进展,2022,(9):799-802.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.008]
　WEN Yan,YANG Mou,HU Hongde.Obstruction Relief Therapy in Obstructive Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(9):799-802.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.008]
点击复制

梗阻性肥厚型心肌病缓解梗阻的治疗进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年9期
页码:
799-802
栏目:
出版日期:
2022-09-25

文章信息/Info

Title:
Obstruction Relief Therapy in Obstructive Hypertrophic Cardiomyopathy
作者:
文琰 杨谋 胡宏德
(四川大学华西医院心脏内科,四川 成都 610041)
Author(s):
WEN Yan ; YANG Mou; HU Hongde
(Department of Cardiology,West China Hospital of Sichuan University,Chengdu 610041,Sichuan,China)
关键词:
梗阻性肥厚型心肌病; 左心室流出道梗阻; 室间隔心肌切除; 酒精室间隔消融; 室间隔射频消融;  立体定向放射治疗
Keywords:
Obstructive hypertrophic cardiomyopathy; Left ventricular outflow tract obstruction; Septal myectomy; Alcohol septal ablation; Septal radiofrequency ablation; Stereotactic radiotherapy
DOI:
10.16806/j.cnki.issn.1004-3934.2022.09.008
摘要:
梗阻性肥厚型心肌病的缓解梗阻治疗是缓解患者的临床症状、提高患者的生存质量以及延长寿命的主要方式。除了传统药物、外科手术、化学消融及起搏器植入，近年来出现的靶向药物、室间隔射频消融、二尖瓣修复和立体定向放射治疗为解除梗阻性肥厚型心肌病的梗阻提供了新的选择。
Abstract:
Obstruction relief therapy o f obstructive hypertrophic cardiomyopathy is the main way to relieve the clinical symptoms,improve the quality of life and prolong the life of patients. In addition to traditional drugs,surgery,chemical ablation and pacemaker implantation,the targeted drugs,ventricular septal radiofrequency ablation,mitral valve repair and stereotactic radiotherapy in recent years provide new options for obstruction relief therapy in obstructive hypertrophic cardiomyopathy

参考文献/References:

[1] Zou Y,Song L,Wang Z,et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China:a population-based echocardiographic analysis of 8080 adults[J]. Am J Med,2004,116(1):14-18.

[2] Veselka J,Anavekar NS,Charron P. Hypertrophic obstructive cardiomyopathy[J]. Lancet,2017,389(10075):1253-1267.

[3] Cardim N,Galderis M,Edvardsen T,et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy:an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association[J]. Eur Heart J Caridovasc Imaging,2015,16(3):280.

[4] Sherrid MV. Drug therapy for hypertrophic cardiomypathy:physiology and practice[J]. Curr Cardiol Rev,2016,12(1):52-65.

[5] Hamada M,Ikeda S,Shigematsu Y. Advances in medical treatment of hypertrophic cardiomyopathy[J]. J Cardiol,2014,64(1):1-10.

[6] Spudich JA. Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations[J]. Pflugers Arch,2019,471(5):701-717.

[7] Anderson RL,Trivedi DV,Sarkar SS,et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers[J]. Proc Natl Acad Sci U S A,2018,115(35):E8143-E8152.

[8] Olivotto I,Oreziak A,Barriales-Villa R,et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy(EXPLORER-HCM):a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet,2020,396(10253):759-769.

[9] Alsulami K,Marston S. Small molecules acting on myofilaments as treatments for heart and skeletal muscle diseases[J]. Int J Mol Sci,2020,21(24):9599.

[10] Liu Y,Song Y,Gao G,et al. Outcomes of an extended Morrow procedure without a concomitant mitral valve procedure for hypertrophic obstructive cardiomyopathy[J]. Sci Rep,2016,6:29031.

[11] Vanderlaan RD,Woo A,Ralph-Edwards A. Isolated septal myectomy for hypertrophic obstructive cardiomyopathy:an update on the Toronto General Hospital experience[J]. Ann Cardiothorac Surg,2017,6(4):364-368.

[12] Rastegar H,Boll G,Rowin EJ,et al. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy:the Tufts experience[J]. Ann Cardiothorac Surg,2017,6(4):353-363.

[13] Collis R,Watkinson O,O’Mahony C,et al. Long-term outcomes for different surgical strategies to treat left ventricular outflow tract obstruction in hypertrophic cardiomyopathy[J]. Eur J Heart Fail,2018,20(2):398-405.

[14] Kim LK,Swaminathan RV,Looser P,et al. Hospital volume outcomes after s eptal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy:US nationwide inpatient database,2003—2011[J]. JAMA Cardiol,2016,1(3):324-332.

[15] Veselka J,Jensen MK,Liebregts M,et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy:results from the Euro-ASA registry[J]. Eur Heart J,2016,37(19):1517-1523.

[16] Veselka J,Faber L,Liebregts M,et al. Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy:a propensity score matching analysis[J]. Eur Heart J,2019,40(21):1681-1687.

[17] Maron BJ,Nishimura RA. Surgical septal myectomy versus alcohol septal ablation:assessing the status of the controversy in 2014[J]. Circulation,2014,130(18):1617-1624.

[18] Chan W,Williams L,Kotowycz MA,et al. Angiographic and echocardiographic correlates of suitable septal perforators for alcohol septal ablation in hypertrophic obstructive cardiomyopathy[J]. Can J Cardiol,2014,30(8):912-919.

[19] Durand E,Mousseaux E,Coste P,et al. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy:early and 6 months follow-up[J]. Eur Heart J,2008,29(3):348-355.

[20]Vriesendorp PA,van Mieghem NM,Vletter WB,et al. Microsphere embolisation as an alternative for alcohol in percutaneous transluminal septal myocardial ablation[J]. Neth Heart J,2013,21(5):245-248.

[21] Lawrenz T,Borchert B,Leuner C,et al. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy:acute results and 6 months’ follow-up in 19 patients[J]. J Am Coll Cardiol,2011,57(5):572-576.

[22] Shelke AB,Menon R,Kapadiya A,et al. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy[J]. Indian Heart J,2016,68(5):618-623.

[23] Liu L,Li J,Zuo L,et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy[J]. J Am Coll Cardiol,2018,72(16):1898-1909.

[24]Zhou M,Ta S,Hahn RT,et al. Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy[J]. JAMA Cardiol,2022,7(5):529-538.

[25] Ma L,Wang L,Tseng CL,et al. Emerging technologies in stereotactic body radiotherapy[J]. Chin Clin Oncol,2017,6(suppl 2):S12.

[26] Townsend RR,Mahfoud F,Kandzari DE,et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications(SPYRAL HTN-OFF MED):a randomised,sham-controlled,proof-of-concept trial[J]. Lancet,2017,390(10108):2160-2170.

[27] Zei PC,Soltys S. Ablative radiotherapy as a noninvasive alternative to catheter ablation for cardiac arrhythmias[J]. Curr Cardiol Rep,2017,19(9):79.

[28] 李慧洋,吴俊劼,周鹏,等. 立体定向射波刀放疗无创性减轻肥厚型心肌病室间隔肥厚的基础及临床探索[J]. 复旦学报(医学版),2022,49(3):1-10.

[29] Afanasyev A,Bogachev-Prokophiev A,Lenko E,et al. Myectomy with mitral valve repair versus replacement in adult patients with hypertrophic obstructive cardiomyopathy:a systematic review and meta-analysis[J]. Interact Cardiovasc Thorac Surg,2019,28(3):465-472.

[30] Shimahara Y,Fujita T,Kobayashi J,et al. Combined mechanical mitral valve replacement and transmitral myectomy for hypertrophic obstructive cardiomyopathy treatment:an experience of over 20 years[J]. J Cardiol,2019,73(4):318-325.

[31] Sorajja P,Pedersen WA,Bae R,et al. First experience with percutaneous mitral valve plication as primary therapy for symptomatic obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2016,67(24):2811-2818.

[32] Daubert C,Gadler F,Mabo P,et al. Pacing for hypertrophic obstructive cardiomyopathy:an update and future directions[J]. Europace,2018,20(6):908-920.

[33] Qintar M,Morad A,Alhawasli H,et al. Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy[J]. Cochrane Database Syst Rev,2012(5):C D008523.

相似文献/References:

[1]熊峰.梗阻性肥厚型心肌病治疗方法的现状与进展[J].心血管病学进展,2019,(6):889.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.013]
　XIONG Feng.Current Status and Progress of Treatment of Hypertrophy Obstructive Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(9):889.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.013]
[2]徐克 孙阳 汪道文.梗阻性肥厚型心肌病的介入和外科手术治疗及进展[J].心血管病学进展,2024,(2):103.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.000]
　XU Ke,SUN Yang,WANG Daowen?/html>.New Perspectives on Interventional and Surgical Treatment for?bstructive Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(9):103.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.000]
[3]姚舜禹 罗素新 黄毕.心肌肌球蛋白抑制剂在梗阻性肥厚型心肌病治疗中的研究现状[J].心血管病学进展,2024,(5):397.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.004]
　YAO Shunyu,LUO Suxin,HUANG Bi.Cardiac Myosin Inhibitors in Treatment of Obstructive Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(9):397.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.004]
[4]李莎 严霜霜 熊峰.Mavacamten在肥厚型心肌病中的治疗进展[J].心血管病学进展,2024,(10):907.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.009]
　LI ShaYAN ShuangshuangXIONG Feng.Advances In the Treatment Of Mavacamten?n Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(9):907.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.009]

备注/Memo

备注/Memo:
收稿日期： 2022-09-05 基金项目：国家重点研发计划资助 (2017YFC1307800)
更新日期/Last Update: 2022-10-21